EUVIMEDEUVIMED entdecken
Open Access

Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer

Jenna N Sjoerdsma, Emily K Bromley, Jaeho Shin, Tyvette Hilliard, Yueying Liu, Caitlin Horgan, Gyoyeon Hwang, Michael Bektas, David Omstead, Tanyel Kiziltepe, M Sharon Stack, Basar Bilgicer

Journal of Controlled Release · 2024-11 · 375 · 438-453

DOI: 10.1016/j.jconrel.2024.09.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-11. Verfasst von Jenna N Sjoerdsma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical & Biomolecular Engineering, University of Notre Dame, Notre Dame, IN 46556, USA; Harper Cancer Research Institute, University …. Hauptthemen laut MEDLINE: Endoplasmic Reticulum Chaperone BiP, Ovarian Neoplasms, Heat-Shock Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of Notre Dame Mike and Josie Harper Cancer Research Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic ovarian cancer (MOC) is highly deadly, due in part to the limited efficacy of standard-of-care chemotherapies to metastatic tumors and non-adherent cancer cells. Here, we demonstrated the effectiveness of a combination therapy of GRP78-targeted (TNPGRP78pep) and non-targeted (NP) nanoparticles to deliver a novel DM1-prodrug to MOC in a syngeneic mouse model. Cell surface-GRP78 is overexpressed in MOC, making GRP78 an optimal target for selective delivery of nanoparticles to MOC. The NP + TNPGRP78pep combination treatment reduced tumor burden by 15-fold, compared to untreated control. Increased T cell and macrophage levels in treated groups also suggested antitumor immune system involvement. The NP and TNPGRP78pep components functioned synergistically through two proposed mechanisms of action. The TNPGRP78pep targeted non-adherent cancer cells in the peritoneal cavity, preventing the formation of new solid tumors, while the NP passively targeted existing solid tumor sites, providing a sustained release of the drug to the tumor microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endoplasmic Reticulum Chaperone BiPOvarian NeoplasmsHeat-Shock ProteinsFemaleAnimalsHumansCell Line, TumorMaytansineAntineoplastic AgentsNanoparticlesMiceNanoparticle Drug Delivery SystemMice, Inbred C57BL

Stichwörter der Autor:innen

Antitumor immune responseLipid nanoparticleMetastasisOvarian cancerTargeted drug deliverywomen's health

Substanzen

Endoplasmic Reticulum Chaperone BiPHspa5 protein, mouseHSPA5 protein, humanHeat-Shock ProteinsMaytansineAntineoplastic AgentsNanoparticle Drug Delivery System

Autor:innen und Institutionen

  • Department of Chemical & Biomolecular Engineering, University of Notre Dame, Notre Dame, IN 46556, USA; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA; Berthiaume Institute for Pre…
  • Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA; Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
  • Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA; Berthiaume Institute for Precision Health, University of Notre Dame, Notre Dame, IN 46556, USA; Department of Chemistry & Biochemist…
  • Department of Chemical & Biomolecular Engineering, University of Notre Dame, Notre Dame, IN 46556, USA; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
  • Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA; Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA. Electronic address: Sharon.Stack.11@nd.…

Förderung

  • NCI NIH HHS
  • University of Notre Dame Mike and Josie Harper Cancer Research Institute
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Sjoerdsma, J. N., Bromley, E. K., Shin, J., Hilliard, T., Liu, Y., Horgan, C., Hwang, G., Bektas, M., Omstead, D., Kiziltepe, T., Stack, M. S., & Bilgicer, B. (2024). Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer. Journal of Controlled Release, 375, 438-453. https://doi.org/10.1016/j.jconrel.2024.09.014

Vancouver

Sjoerdsma JN, Bromley EK, Shin J, Hilliard T, Liu Y, Horgan C, et al. Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer. Journal of Controlled Release. 2024;375:438-453. doi:10.1016/j.jconrel.2024.09.014

BibTeX
@article{Sjoerdsma2024,
  author = {Sjoerdsma, Jenna N and Bromley, Emily K and Shin, Jaeho and Hilliard, Tyvette and Liu, Yueying and Horgan, Caitlin and Hwang, Gyoyeon and Bektas, Michael and Omstead, David and Kiziltepe, Tanyel and Stack, M Sharon and Bilgicer, Basar},
  title = {Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {375},
  pages = {438--453},
  doi = {10.1016/j.jconrel.2024.09.014}
}
Kostenlos starten →